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Some of the results of this study have been reported in the form of an abstract (Dilektasli AG, 
Porszasz J, Stringer WW, Pak Y, Rossiter HB, Casaburi R, Hansen JE for the COPDGene 
Investigators. A New Bronchodilator Response Grading Strategy Based on Distribution of FEV1 
Increase Identifies Clinically Distinct Patient Groups in the COPDGene Cohort. American 
Journal of Respiratory and Critical Care Medicine 2018;197:A2450.). 
 
This article has an online supplement.
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ACO: asthma-COPD overlap 
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BDR: bronchodilator response 
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CV: coefficient of variation 
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FVC: forced vital capacity  
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Pre-BD: pre-bronchodilator 
Segmental WA%: segmental airway wall area percentage 
SGRQ: St. George¶V Respiratory Questionnaire 
6MWT: six-minute walking test  
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Abstract  
Background: A positive bronchodilator response (BDR) by American Thoracic 
Society/European Respiratory Society (ATS/ERS) guidelines requires an increase in FEV1 or 
FVC t200 mL and 12% after bronchodilator inhalation. This dual criterion is insensitive in those 
with high or low FEV1. We aimed to establish BDR criteria with volume or percentage FEV1 
change.  
Methods: The largest FEV1 and FVC were identified from 3 pre- and 3 post-bronchodilator 
maneuvers in COPDGene participants. 7,741 individuals with coefficient of variation <15% for 
both FEV1 and FVC formed bronchodilator categories of FEV1 response: negative (0.00% or 
/), minimal (>0.00% to 9.00% or >0.00L to 0.09L), mild (>9.00% to 16.00% or 
>0.09L to 16L), moderate (>16.00% to 26.00% or >0.16L to 0.26L), and marked 
(>26.00% or >0.26L). 
 
These response-size categories are based on empirical limits considering 
average FEV1 increase of ~160 ml and the clinically important difference for FEV1. To compare 
flow and volume response characteristics, BDR-FEV1 category assignments were applied for the 
BDR-FVC response.  
Results: 20% met mild and 31% met moderate or marked BDR-FEV1 criteria; whereas 12% met 
mild and 33% met moderate or marked BDR-FVC criteria. In contrast, only 20.6% met 
ATS/ERS positive criteria. Minimal, mild, moderate and marked BDR-FEV1 categories were 
associated with greater six-minute walking distance, lower St. George¶V Respiratory 
Questionnaire and mMRC dyspnea scores as compared to those in negative BDR-FEV1 category. 
Moderate and marked BDR-FEV1 categories were associated with fewer exacerbations and 
minimal BDR was associated with lower computerized tomography airway wall thickness 
compared to negative BDR. Compared with negative, all BDR-FVC categories were associated 
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with increasing emphysema% and gas trapping%. Moderate and marked BDR-FVC categories 
were associated with higher SGRQ scores but fewer exacerbations and lower dyspnea scores. 
Conclusions: BDR grading by FEV1 volume or percentage response identified subjects 
otherwise missed by ATS/ERS criteria. BDR grades were associated with functional exercise 
performance, quality of life, exacerbation frequency, dyspnea and radiological airway measures. 
BDR grades in FEV1 and FVC indicate different clinical and radiological characteristics. 
Keywords: airflow obstruction, bronchodilator responsiveness, FEV1 
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Introduction 
Current criteria for identifying a positive spirometric bronchodilator response (BDR) 
based on American Thoracic Society (ATS) and European Respiratory Society (ERS)1 guidelines 
require both 200mL and 12% increase in forced expiratory volume in 1 second (FEV1) or forced 
vital capacity (FVC). If these dual criteria are not met, BDR is categorized as negative. These 
guidelines may not identify many individuals with potentially clinically important BDR, 
especially those with low baseline FEV1 who do not meet ¨ P/, or those with high baseline 
FEV1 who do not meet ¨ %2-4. Both Pellegrino and Brusasco5 and Calverley et al.6 
emphasized that FEV1 BDR is a continuous variable; no threshold adequately separates 
responders from non-responders. Hansen et al.4, analyzing BDR in a sample of clinical pre- and 
post-bronchodilator tests, showed that 224 of 313 patients (71.6%) failed ATS/ERS FEV1 
criteria, but 89 (39.7%) of those 224 who failed showed statistically significant 'FEV1 mL 
RULPSURYHPHQW. Of those with baseline FEV1 <1L (n=44), 52.3% had 'FEV1 PL or 
while only 11.4% were ATS/ERS positive3. These results suggest the need to revise BDR 
evaluation. 
The COPDGene population, with 10,311 current or ex-smokers with or without 
spirometrically defined COPD, is uniquely positioned to evaluate BDR7 and forms the basis of 
the current evaluation. 
We aimed to: a) develop a new grading system based on BDR volume or percent 
increase, for comparison with ATS/ERS guidelines, b) HYDOXDWH$76(56UHFRPPHQGHG¨)(91 
YHUVXV¨)9&YDOXHV, and c) explore clinical relevance of the new BDR grades by comparing 
them to clinical outcomes and pulmonary structural characteristics.  
 
Materials and Methods  
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We utilized the COPDGene cohort enrolled between 2007 and 20117. This cohort 
included 10,311 non-Hispanic whites and African-Americans, 45-80 years old, with 10 pack-
years smoking history. Key exclusion criteria were history of other lung disease (except asthma), 
or previous lung resection (see online supplement)7. Participants underwent spirometry, six-
minute walking test (6MWT), quantitative computerized tomography (CT) and standard 
questionnaires to assess symptoms and medical history. From this population, participants who 
did not have FEV1, FEV6 and FVC values from 3 pre-bronchodilator and 3 post-bronchodilator 
maneuvers were excluded (n=2,084) as were those with coefficient of variance (CV, standard 
deviation/mean) of either pre-bronchodilator or post-bronchodilator blows >15% (n=486)8, 
reducing the study population to 7,741. The COPDGene protocol was approved by Institutional 
Review Boards at 21 participating centers. Written informed consent was obtained from all 
participants. 
 
Spirometry and proposed BDR grades  
Spirometry was performed in accordance with ATS/ERS recommendations and using an 
ultrasound-based spirometer (NDD, EasyOne Spirometer Medizintechnik AG, Zurich, 
Switzerland) before and after two puffs of albuterol using a spacer9. Before bronchodilator 
reversibility testing, short-acting and long-acting inhaled bronchodilators were withheld 4 and 12 
hours; short-acting and long-acting oral bronchodilators were withheld 8 and 12 hours prior to 
testing, respectively. The largest of 3 acceptable FEV1 and FVC measurements were reported. 
Spirometric measurements were graded (range 04) by a centralized quality control process 
(range 04: Grade 4: fully met ATS criteria, reproducible to within 50mL, Grade 3: fully met 
ATS criteria, reproducible to between 50-100mL, Grade 2: fully met ATS criteria, reproducible 
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between 100-150mL, Grade 1: partly meeting ATS criteria and/or reproducible between 150-
200mL, Grade 0: failure to meet ATS criteria and/or reproducible greater than 200mL)10. Pre-
bronchodilator quality control grades for FEV1 and FVC were 3.54r0.78 and 3.35r0.92, whereas 
post-bronchodilator quality control grades were 3.62r0.70 and 3.46r0.81, respectively, in the 
study group. These grades did not differ markedly among BDR categories (Table 2).  
BDR was evaluated as absolute change from baseline FEV1 ('FEV1L) and percentage 
change from baseline FEV1 ('FEV1%). BDR is a continuous variable with an unimodal, not 
bimodal, response pattern11. Using fixed population-based criteria for both volume and 
percentage change in BDR is not optimal, especially considering differences in drug, dosage and 
administration methods in published studies4.  We used five bronchodilator categories of FEV1 
response by using volume or percentage FEV1 change: negative (0.00% or /), minimal 
(>0.00% to 9.00% or >0.00L to 0.09L), mild (>9.00% to 16.00% or >0.09L to 16L), 
moderate (>16.00% to 26.00% or >0.16L to 0.26L), and marked (>26.00% or >0.26L) BDR. 
 
The rationale for the five-point grading system including non-responders (negative), and 
minimal, mild, moderate and marked responders is based on several considerations: 'FEV1L 
clearly defines the non-responder and negative responder category. We have previously asserted 
'FEV1% of 6 or 7% might be clinically important as it is associated with about a 90 to 100mL 
increase in FEV13, which has been suggested as the minimum clinically important difference 
(MCID) for 'FEV112; we use 90mL or 9% to separate minimal from mild response. A 9% 
threshold, corresponding to upper 95th percentile of BDR in FEV1, was previously proposed to 
define clinical ³DEQRUPDOLW\´EDVHGon BDR in a large group of asymptomatic never-smokers13. 
After excluding non-responders, when we ordered responses by baseline FEV1, average 'FEV1 
in groups of 100 persons seemed to stabilize at ~160 ml ('FEV1L and 'FEV1% profile in Figure 
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1). This value (and the corresponding 16% change) was chosen to separate the mild and 
moderate categories. Previously, absolute increase in FEV1 required to exclude natural 
variability with 95% confidence was reported as 160 mL in obstructive airway disease14. In 
distinguishing between moderate and marked response it seemed practical to utilize a further 100 
ml MCID step-size, and use 260 mL or 26% increase.  For ATS/ERS guidelines comparison, we 
placed participants LQWR$76(56JURXSVIRU¨)(91: 1) Positive: ¨FEV1L 0.2 L and ¨)(91% 
 and 2) Negative: all others. To compare flow and volume response characteristics in 
bronchodilator testing, we also evaluated BDR in FVC (BDR-FVC). BDR-FVC was evaluated as 
absolute change from baseline FVC ('FVC L) and percentage change from baseline FVC 
('FVC %). We utilized the same BDR category assignments we derived for FEV1 for the BDR-
FVC response.  
Clinical and functional correlates 
As clinical and functional correlates we used 6W*HRUJH¶V5HVSLUDWRU\4XHVtionnaire 
(SGRQ) to assess health-related quality of life (scores ranging from 0-100, where a greater score 
indicates worse health status)15, modified Medical Research Council (mMRC) dyspnea scale to 
quantify dyspnea (scores ranging from 0 to 4, a greater score indicates worse dyspnea 
perception)16, and six-minute walking distance (6MWD) to assess functional exercise 
performance. Six-minute walking test was performed according to ATS standards17, and at least 
20 minutes after albuterol administration for post-bronchodilator spirometry. Exacerbation 
frequency in the prior year was recorded at enrollment, with exacerbations defined as acute 
worsening of respiratory symptoms requiring antibiotics and/or systemic corticosteroids 18. CT 
scans were acquired at full inspiration and end-expiration (see online supplement). CT scans 
were obtained after bronchodilator testing. Airway wall thickness was assessed by segmental 
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airway wall area percentage (segmental WA% = (outer bronchus area ޤ airway luminal area) / 
outer bronchus area), and square root wall area of a 15mm diameter airway (Pi15)19. 
Emphysema% on CT was defined as percentage of low attenuation areas below 950 Hounsfield 
Units (HU) on end-inspiratory CT scan20. Gas trapping% was defined as %lung voxels below 
856 HU on expiratory scans21. 
Statistical analyses  
SPSS 22.0 (IBM Corp: Armonk, NY) and Stata 15 (StataCorp LLC: Texas) procedures 
were used. Univariate analyses were performed between BDR grades using Chi-square test for 
proportions and one-way ANOVA or Kruskal-Wallis test for continuous variables (Table 2 and 
Table E1). P-values for pair-wise comparisons were adjusted for overall type-II error rate (5%) 
XVLQJ7XNH\¶VPHWKRG. Relationships between BDR grades (independent variable) and 
quantitative CT, SGRQ and 6MWD (dependent variables) were assessed by general linear 
regression models using age, sex, race, smoking history, body mass index (BMI), baseline FEV1 
and CT scanner type (only for CT measures) as covariates (separately for BDR-FEV1 and BDR-
FVC response) (Tables 3 and 5). A proportional odds model was used for mMRC (Tables 3 and 
5). A generalized linear regression model with negative binomial link function assessed BDR 
grade¶VLQGHSHQGHQWHIIHFW on exacerbation frequency22 (Tables 3 and 5). SGRQ, emphysema% 
and gas trapping% were natural-log transformed; regression coefficients for natural-log 
transformed variables were back-transformed and exponentiated beta values were presented to 
aid interpretation. Finally, to assess the relation between BDR (as separate continuous variables: 
'FEV1L, 'FEV1%, 'FVC L, 'FVC%) and 6MWD, SGRQ and quantitative CT measures, we 
modeled 6MWD, SGRQ and quantitative CT measures against 'FEV1L, 'FEV1%, 'FVC L, and 
'FVC% in the whole study population. 'FEV1L, 'FEV1%, 'FVC L, and 'FVC% were coded 
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using restricted cubic spline function with three knots, located at the 5th, 50th, and 95th percentiles 
(Figure 4A, 4B). All these models were adjusted for age, sex, race, smoking history, BMI, 
baseline FEV1 or FVC, and CT scanner type (for CT measures). 
Analyses were performed for the whole study population. ATS/ERS criteria identified 
most of the participants in the marked BDR category as positive BDR. Accordingly, analyses 
were performed in the subgroup after excluding ATS/ERS positives (Table 5). But excluding 
ATS/ERS positives causes a substantial loss in sample size of marked BDR group. For that 
reason marked BDRs were excluded from the subgroup analysis. 
Results  
Characteristics of the 7,741 participants are summarized in Table 1. Within subject CV 
for pre-and post-bronchodilator FEV1 was 4.12%r2.77% and 3.52%r2.54%, respectively.  
Distributions of absolute and percentage FEV1 BDR are presented in Figure 2. Mean 'FEV1L 
and 'FVCL were 0.099L and 0.092L, respectively. However, 'FEV1L and 'FEV1% 
distributions were dramatically different (Figure 2). This emphasizes that volume and percentage 
changes need to be considered separately from each other. Table 2 shows study participants 
graded by BDR intensity categories. Total BDR positives were 78.9%.  
'FEV1L and 'FVCL after bronchodilator inhalation are presented in Figure 3. Despite 
similarity of mean and SD (Table 1)¨)9&L increased more rapidly than ¨FEV1L above a BDR 
of 0.1L (Figure 3A). In contrast, ¨FEV1% and ¨FVC% increased similarly over the full BDR 
range (Figure 3B).  
In Figure 1, 'FEV1L and 'FEV1% of positive BDR participants are ordered by 
increasing pre-BD FEV1 volumes to compare volume and percentage increase patterns. 
Conspicuously, BDR patterns expressed as 'FEV1L and 'FEV1% differed markedly as pre-
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bronchodilator FEV1 increased. Below pre-bronchodilator FEV1%pred of 40% ( FEV1 ~1 L), 
¨FEV1L increased rapidly up to ~0.160 L and then stabilized, whereas ¨FEV1% averaged ~16% 
then gradually declined in a hyperbolic fashion to ~4% as FEV1 increased.  
 
BDR categories by FEV1 response 
Utilizing proposed BDR cut-offs, 27.9%, 20.0%, 18.1% and 12.9% of the population had 
minimal, mild, moderate and marked bronchodilator response, respectively (Table 2). 100% of 
the minimal responders had a minimal FEV1-BDR by both 'FEV1L and 'FEV1%.  93.1% and 
25.6% of the mild responders had mild BDR by 'FEV1L and 'FEV1%.  91.6% and 20.7% of the 
moderate responders had moderate BDR by 'FEV1L and 'FEV1%.  91.0% and 27.7% of the 
marked responders had marked BDR by 'FEV1L and 'FEV1%, respectively. On the other hand, 
21.1% of the population had a negative BDR response. Mean ages of marked bronchodilator 
responders and non-responders were lower than that of minimal, mild and moderate responders. 
Female sex was more prominent in minimal and mild, whereas male sex was more prominent in 
marked and non-response categories. Negative responders had greater pre- and post-
bronchodilator FEV1/FVC compared to all other response categories.  
In the univariate analyses, there was progressive increase in segmental WA% from 
negative to marked BDR (p<0.0001). Pi15 increased from minimal to marked bronchodilator 
responders (p<0.0001). Marked BDR-FEV1 group  had significantly greater segmental WA% 
and Pi15 compared to minimal, mild, moderate BDR-FEV1 groups and non-responders (adjusted 
p=0.0005 for post-hoc comparisons, not shown). 6MWD increased from 408r123m to 
431r117m as BDR-FEV1 increased from minimal to marked (p<0.0001). We also observed 
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significant differences in SGRQ, mMRC scores and exacerbation frequency between BDR-FEV1 
groups (Table 2). 
After adjusting for potential confounders, including sex, age and baseline FEV1, patients 
with greater BDR-FEV1 had greater 6MWD, better SGRQ, fewer exacerbations and lower 
mMRC (Table 3).  There was a significant decrease in odds of being in higher mMRC category 
as BDR-FEV1 category increased from minimal to marked. Mean WA and Pi15 of marked BDR-
FEV1 were 0.29% and 0.03mm greater compared to negative responders, respectively. 6MWD 
was 37 meters greater in marked BDR compared to negative responders. SGRQ was 12% less in 
moderate and marked BDR-FEV1 group compared with negative responders. Relative risk of 
annualized exacerbation rate were 26% and 14% decreased in marked and moderate FEV1-
bronchodilator responders compared to negative category, respectively (relative risk, 0.86, 
p=0.044 and 0.74, p<0.00001, respectively). On the other hand, mean WA% and Pi15 were 
0.24% and 0.01mm less in minimal FEV1-bronchodilator responders compared to negative 
responders. In models assessing the relationship between 'FEV1L and 'FEV1%, as continuous 
variables (Figure 4A), 6MWD increased with an upward slope as 'FEV1 L increased, whereas 
6MWD decreased with a downward slope as 'FEV1% increased in participants with a positive 
BDR. The relation between SGRQ score with 'FEV1% had an upward slope in positive BDRs. 
The relationship of 'FEV1% with both WA segmental% and Pi15 was more pronounced with a 
steeper upward slope than for 'FEV1L. 
Comparison of BDR- FEV1 Grading Strategy with BDR by ATS/ERS criteria  
Comparison of BDR using ATS/ERS criteria to the proposed BDR grades shows striking 
differences (Table 4). ATS/ERS criteria identify only 20.6% of patients as positive BDR, 79.4% 
in the marked category, 32.3% in the moderate category, and only 8.8% in minimal and mild 
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BDR-FEV1 categories. Almost 4/5 of the marked BDR group (794 of 1000) was also ATS/ERS 
positive. When we analyzed correlates of BDR grades after excluding ATS/ERS positives in the 
minimal, mild, and moderate BDR categories; we observed that minimal, mild, and moderate 
BDR-FEV1 were associated with greater 6MWD and lower SGRQ compared to negative BDR 
category. Odds of being in a higher mMRC category decreased as BDR-FEV1 increased from 
minimal to moderate when compared to non-responders (Table 5).  
BDR Grading Strategy applied for BDR in FVC 
By utilizing proposed BDR cut-offs, 16.4%, 12.0%, 12.1% and 22.2% of the population 
had minimal, mild, moderate and marked FVC-bronchodilator response, respectively (Table 3). 
37.3% of the study population had a negative BDR in FVC. Pre-bronchodilator FEV1, FVC and 
FEV1/FVC decreased as volume response increased from minimal to marked FVC-
bronchodilator response. In the univariate analyses (online supplement, Table E1), total SGRQ 
and dyspnea scores, exacerbation frequency, segmental WA%, emphysema% and gas trapping% 
increased as FVC-bronchodilator response increased from negative to marked (p<0.0001). 
After adjusting for potential confounders including baseline FVC, patients with greater 
BDR-FVC had greater emphysema and gas trapping and fewer exacerbations and lower mMRC 
(Table 3).  Emphysema and gas trapping were 50% and 46% greater in marked BDR compared 
to negative responders, respectively. Mean WA and Pi15 of marked BDR-FVC were 0.67% and 
0.04mm greater compared to negative responders, respectively. 6MWD was a14 meters greater 
in marked BDR-FVC compared to negative responders. SGRQ was 9% and 14% higher in 
moderate and marked BDR-FVC compared with negative responders. Participants in mild, 
moderate and marked BDR-FVC categories were less likely to experience exacerbations 
compared to negative responders. There were significantly decreased odds of being in higher 
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mMRC category in moderate and marked BDR-FVC categories. On the other hand, mean Pi15 
was 0.02mm less in minimal BDR-FVC group compared to negative BDR-FVC responders. 
In models assessing the relationship between 'FVC L and 'FVC %, as continuous 
variables (Figure 4B), total SGRQ score, emphysema% and gas trapping% were lowest in the 
region of 'FVC L and 'FVC % levels around -1.5 Liters and -40%, respectively. After those 
regions, there was a trend of increasing total SGRQ score, emphysema% and gas trapping% with 
an upward slope as 'FVC L and 'FVC % increased. 
 
Discussion  
Our approach of identifying distribution characteristics of BDR is an improvement in 
evaluating clinical and radiological associations of bronchodilator responsiveness. Grading 
systems using several categories might be more useful than those yielding only positive/negative 
categories. These data demonstrate the importance of separating volume and percentage BDR 
change rather than requiring both simultaneously, which biases against identifying meaningful 
BDR in subjects with small or large FEV1.  
Our categorization employs identical numerical IUDFWLRQVIRU¨FEV1 in L and in % units. 
It yields many more positive responders than does ATS/ERS positive criteria (Table 4). 
Logically, patients with low FEV1 should benefit more from small FEV1 volume increases than 
those with large FEV1. Advantageously, for the 7,741 individuals studied, our grading method 
identified 80% with at least minimal and 50% with moderate or greater FEV1 BDR, while the 
ATS/ERS method identified only 20.6% positive. 
 Interpretation of BDR for obstructive airways disease (OAD) patients in pulmonary 
laboratories has long been disputed. Nearly fifty years ago, Freedman et al. suggested that most 
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physicians would agree that a FEV1 increase <10% is valueless and that a 20%-30% increase 
was likely useful23.  In 1974, a CHEST advisory committee recommended positive BDR 
required FEV1 change in both percent and absolute volume24. In 1982, Ries recommended an 
FEV1 increase of both 15% and 200mL25. Eliasson et al.26, reviewing 66 asthma and COPD 
papers, found that 14 papers used seven different BDR criteria. In 1991, an ATS committee 
recommended increase in FEV1 or FVC t200 mL and 12% 27. This criterion was reinforced in 
the 2005 ATS/ERS guidelines1. Considering that baseline FEV1 of individuals assessed for BDR 
vary over a wide range28, to exceed healthy population-based confidence intervals29 for both 
volume and percentage values to establish positive bronchodilator response may be too 
restrictive.  
In a 2011 review, Hanania et al.30 examined the 5 most prevalent recommendations: 
including %predicted FEV1 >10% (ERS31), FEV1 increase >15% (ACCP24) and >12% and 
200mL increase (ATS27, ATS/ERS1 and GOLD18). In response to a letter by Hansen et al.32, 
Hanania et al. agreed that BDR response of <200mL in those with low baseline FEV1 was 
clinically valuable33. In 2005, Donahue12 recommended that >100mL FEV1 increase in OAD 
patients is likely to be clinically important. 
 BDR may be expressed in alternate ways: as absolute change in values, as percentage 
change from baseline, or as change as a percentage of the VXEMHFW¶V predicted value34,35. Using 
change in FEV1 as % predicted was recently shown to avoid sex and size bias in the assessment 
of BDR34. Although there is no consensus on how a BDR should be expressed in the literature, 
most guidelines express BDR as absolute change in values and as percentage change from 
baseline, we employed this strategy. Additionally, in the presence of severe airway disease such 
as COPD, the baseline FEV1 may be far off the predicted value which may cause an 
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underestimation of the BDR as compared to performance of the subject variable (change in FEV1 
as % predicted) in relatively more healthy or non-smoker populations. 
  
BDR category assignments  
 Dividing BDR data into grades has often used only mean and SD values. In our study 
population, using a grading approach based on 'FEV1L or 'FEV1% distribution and means 
(Figure 2) might cause an unbalanced strategy, since ±1 SD of ¨volume would assimilate ~68% 
of participants into one BDR class, with the remaining ~32% divided into several much smaller 
classes (e.g., ±2 SD, ±3 SD). Instead, our grading strategy is based upon profile of changes in 
volume and percentage change in FEV1 (Figure 1) and other considerations to establish grading 
category cutoffs. This resulted in BDR response of this population being classified 21% 
negative, 28% minimal, 20% mild, 18% moderate and 13% marked. 
 Of the 7741 participants, 21.1% had negative bronchodilator response by FEV1, 
compared to 37.3% by BDR-FVC. Although BDR-FVC was more frequently reported in COPD 
patients than that of FEV1 response36,37, we observed that BDR by FEV1 was more common than 
BDR by FVC in our study population. FVC has the disadvantage of being dependent on 
expiratory time38. Therefore, evaluation of BDR by FVC may be noisy39. Figure 3 shows that, 
for ¨FEV1L BDR of >100mL, the number of individuals meeting any specific volume criterion 
is much greater for FVC than for FEV1, while for those meeting ¨FEV1% criteria >10% are 
similar for FVC and FEV1.  In COPD patients, the magnitude of the flow ('FEV1) and volume 
('FVC)
 
responses after administration of albuterol differ. A particular flow response is 
accompanied by a higher volume response as the severity of airflow obstruction worsens in 
COPD. In our study, 'FEV1 and 'FVC responses were similar between BDR categories (Table 
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2). This finding may be a result of our study population consisting of smokers, with almost 50% 
without airflow obstruction. 
 
Clinical implications of BDR grades  
Our results indicate that spirometric indices and CT measures of airway wall thickness 
increase as BDR increases. In accordance with reports suggesting inverse correlation between 
spirometric obstruction and bronchodilator response, baseline FEV1/FVC decreased as BDR 
response increased26. We observed significant increase in segmental WA% and Pi15 as BDR 
increased from minimal to marked (Table 2). Similar trends persisted when we adjusted CT 
outcomes for baseline FEV1 and other potential confounders. Kim et al. found that airway wall 
thickness independently predicted BDR in COPD and suggested that increased CT airway wall 
thickness in the BDR positive COPD group represented airway pathology dominated by smooth 
muscle hypertrophy40. Morphometric studies in asthmatics revealed bronchial tree zones with 
significant muscular hypertrophy, reflecting hyperreactivity of these segments41. Both the 
segmental WA% and Pi15 mainly reflect large airways. We think that our findings showing 
significant BDR dependence in segmental WA% and Pi15 may reflect an increased bronchomotor 
tone due to smooth muscle hypertrophy in the large airways of smokers with marked 
bronchodilator response.  
To our knowledge, our results indicate for the first time that 6MWD  a marker of 
functional exercise performance  significantly and continuously increases as acute 
bronchodilator response grade increases. This finding is in agreement with Anthonisen and 
Wright¶VLQLWLDOREVHUYDWLRQV, reporting a relatively well-preserved exercise tolerance in COPD 
patients with large bronchodilator responses42. The mechanism underlying this observation is not 
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known but one possible explanation is that patients with a larger BD response are able to 
bronchodilate during the hyperpnea of exercise. Despite that the relationship between the 6MWD 
and 'FEV1L were similar to that of 6MWD and BDR-FEV1 response grades, the relationship 
between the 6MWD and 'FEV1% had an inverse relation (Figure 4A). One possible explanation 
for the difference between results of continuous modeling of 6MWD vs. FEV1% and 'FEV1% 
may be the fact that > 90% of the responders in each BDR category were positive by volume 
change in FEV1. For that reason, associations with BDR grades may be dominated by 
associations with volume change in FEV1´ 
Recently, Quanjer et al. suggested that an ideal BDR measure should be based on clinical 
outcomes, such as exacerbations, quality of life and hospitalizations11. Not long before, Albert 
and colleagues suggested that BDR did not distinguish clinical outcomes such as mortality or 
exacerbation rates in the ECLIPSE COPD cohort43. We observed significant increase in quality 
of life as BDR grade increased from minimal to marked. Supportingly, a greater SGRQ score 
was reported in poorly responsive moderate-to-very severe COPD patients in UPLIFT44. 
Moreover, to our knowledge, our analysis is the first to show exacerbation frequency reduction 
irrespective of baseline FEV1 in patients with moderate and marked BDR compared to negative 
responders. Our analysis characterizes a group of marked BD responders with more airway 
disease, evidenced by greater segmental WA% and Pi15, better preserved exercise performance 
and dyspnea, greater quality of life and fewer exacerbations compared to negative responders. 
Associations observed for 6MWD in the multivariable models are greater than their MCIDs45,46. 
Associations for exacerbations and CT measures can only be evaluated statistically, since 
validated MCIDs for those outcomes do not yet exist47.   
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When we applied BDR Grading Strategy for a FVC based BDR, we observed that 
emphysema% and gas trapping% increased as BDR in FVC increased from minimal to marked 
category. Emphysema and gas trapping were prominent features of BDR-FVC responders in 
accordance with previous reports 48-50. Cerveri et al. have shown that FVC responder COPD 
patients have more severe emphysema than both FEV1 and FVC responders48. Further, 
Deesomchok et al. have shown that COPD patients with greatest resting lung hyperinflation 
shows the largest bronchodilator-induced volume response in reversibility testing49. The greater 
volume response compared to flow response in COPD patients was explained by the presence of 
a higher degree loss of lung elastic recoil due to emphysema and compression of small airways 
by the enlarged airspaces as the airflow obstruction worsened48. In addition to previously 
reported findings, BDR grading strategy defined in current study were successful in capturing an 
increasing trend in emphysema and gas trapping extent as BDR in FVC increased from minimal 
to marked response categories compared to non-responders.  
 
BDR-FVC is associated with gas trapping. This finding is in agreement with literature 
findings50,51. Gas trapping on quantitative CT is accepted as a prominent sign of small airways 
disease. Supportingly, small airways diameter on spiral CT scan was previously shown to narrow 
in FVC responder COPD patients48. There was an inverse association with BDR-FVC response 
and exacerbation frequency in patients with mild-to-marked BDR-FVC compared to negative 
responders. Further, quality of life was impaired in moderate and marked BDR-FVC compared 
with negative responders. We theorize that impaired quality of life and increased exacerbation 
frequency observed in these patients may be a consequence of severe hyperinflation and 
emphysema present in moderate and marked BDR-FVC responders. 
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In this study, we demonstrate that BDR-FEV1 and BDR-FVC are associated with 
different clinical, functional and radiological characteristics. While increasing bronchodilator 
response in FEV1 is primarily associated with improving 6MWD, quality of life, and dyspnea, 
increasing bronchodilator response in FVC is primarily associated with increasing emphysema 
and gas trapping. Moderate or marked BDR in both measures are associated with a reduction in 
exacerbation frequency. 
A very recent paper aimed to examine clinical, functional and radiological associations of 
BDR by ATS/ERS criteria50. In subjects with spirometrically-defined COPD, the authors have 
shown that ATS-BDR positive participants in the COPDGene population were associated with 
higher %gas trapping, Pi10, functional small airways disease, FRC and TLC% predicted, 
respiratory exacerbations and 6MWD compared to non-BDR group. In our study, which studied 
the responses of subjects with smoking history with and without spirometric evidence of COPD, 
ATS/ERS criteria identified most of the participants (79.4%) in the marked category as positive 
BDR.  Despite this important clinical association of the ATS/ERS BDR criteria50, when we 
excluded BDR positive participants by ATS/ERS criteria, we observed that clinical associations 
of BDR Grading Strategy persisted for 6MWD, SGRQ and mMRC in the adjusted multivariable 
analysis: patients with greater BDR had greater exercise performance, better quality of life and 
less dyspnea perception (Table 5). 
We observed that 21.1% of our study group had a negative response (defined as 0.00% 
or / FEV1 change) to albuterol. Recently, Bhatt and colleagues showed that a paradoxical 
response to beta-2 agonists resulting in bronchoconstriction was associated with respiratory 
morbidity measured by higher mMRC, frequent exacerbations and lower 6MWD52. Probably, 
some of the participants in negative response category in our study can be regarded to have a 
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paradoxical response to beta-2 agonists. Despite the negative category being set as the reference 
category in our analyses, our results are partly in accordance with Bhatt and colleagues 
observations, by showing a decreasing quality of life and 6MWD as BDR decreased, increasing 
odds for experiencing a higher dyspnea level as BDR decreased and decreasing odds for 
frequency of exacerbations in patients with marked and moderate BDR compared to negative 
response category. 
In the whole study group, patients with minimal BDR-FEV1 compared to those with mild, 
moderate and marked BDR-FEV1 had lower exercise performance, lower quality of life and 
more dyspnea perception (Table 3). It seems logical to assume that, the minimal BDR-FEV1 
group is likely to have fixed airways obstruction, since their airways respond minimally to 
albuterol inhalation.  
 
Relevance to ACO phenotype 
Bronchodilator responsiveness is accepted as the key feature of asthma and COPD 
overlap (ACO) phenotype53. Although different definitions for ACO are used in various studies, 
a spirometric component of a widely used ACO definition requires a marked bronchodilator 
response (>400 mL) or at least a positive bronchodilator response (t200 mL and 12%) in 
addition to persistent airflow limitation53-55. It might be asked whether the characteristics of the 
participants with marked bronchodilator response in our study resembled clinical features of 
patients with ACO. Cosentino et al. found that ACO subjects had less severe spirometric and 
radiological findings (less emphysema and gas trapping), but more segmental airway wall 
thickening and they were more likely to experience frequent exacerbations compared to COPD 
subjects56. Although there are several published studies aiming to characterize clinical features of 
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ACO phenotype in the COPDGene population56-58, their analysis is usually limited to comparing 
features of ACO patients with either COPD or asthma alone, rather than comparing ACO 
characteristics with an overall smoker population. Having shown clinical implications of various 
degrees of bronchodilator response (much less than 400 mL), we suggest considering the use of 
bronchodilator grading, rather than an all or none evaluation system, for further ACO 
phenotyping studies. 
Tweddale and colleagues14 reported that, in patients with reduced FEV1/VC ratio, 
absolute FEV1 increase required to exclude natural variability with 95% confidence was 160 mL. 
In this context, minimal and mild categories in the proposed BDR grading system fall in the 
range of this natural variability. But, in our analysis we observed that minimal and mild BDR 
categories are associated with important patient-centered outcomes in COPD (greater 6MWD, 
lower SGRQ and mMRC dyspnea scores) compared to negative BDR. The fact that 
bronchodilator response below variability thresholds may associate with symptom and 
performance improvements (perhaps because BDR may be unpredictably underestimated by 
FEV1 and/or FVC changes in some cases) is also acknowledged in ATS/ERS 2005 guideline9. 
Further, BDR to a short acting bronchodilator is no longer recommended to predict long term 
response and is not thought helpful in making therapeutic decisions11. Therefore, we believe this 
VWXG\¶VILQGLQJVDUHKHOSIXOWRcharacterize clinical associations of bronchodilator responsiveness 
rather than using them to make therapeutic decisions. We hope that our findings, in addition to 
recently reported studies that characterize BDR,11,34 will spur guideline committees to revisit 
current BDR criteria.  
Our study has several limitations. Although we utilized a large population, it includes 
only current and ex-smokers. A population-based sample of 3922 healthy non-smokers showed 
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that the upper 95% confidence limit for BDR was 284 ml for 'FEV1 and 12% for 'FEV1%29. In 
the ECLIPSE cohort, FEV1 changes after an inhaled bronchodilator in smoking controls and 
COPD patients were significantly greater than in non-smoking controls34,43. Importantly, healthy 
never-smokers were not included in our cohort, which restricts generalisability of our results to 
this group. Second, whether other inhaled bronchodilators or other albuterol doses should be 
similarly graded is untested. Third, observations from various cohorts have shown that the 
presence of BDR is variable over time59-61. Unfortunately, our study does not include 
longitudinal analysis of the study cohort to allow examination of long-term implications of BDR 
categorization. Fourth, when defining thresholds for the BDR grading system, in distinguishing 
between moderate and marked response, a 100 mL MCID step-size was utilized.  But, 100 mL as 
a MCID for FEV1 was based on a single study that enrolled only COPD patients, which limits 
the generalizability of 100 mL MCID value to populations other than COPD12. Fifth, we 
acknowledge that the thresholds for the BDR grading system were derived for FEV1 change.  
These thresholds may not be fully applicable to FVC change.  Further study will be necessary to 
determine whether different thresholds may perform better for FVC response.  
Lastly, blood eosinophils have strong potential as a prognostic and therapeutic biomarker 
in the clinical management of COPD. To evaluate association of bronchodilator responsiveness 
with blood eosinophil count would be a promising analysis for further research.  
In conclusion, BDR in current- or ex-smokers can be graded by using either volume or 
percentage change in FEV1 or FVC. Our findings, based on the largest smoker population with 
quantitative CT data, suggest that this BDR grading system identified patients with clinically 
important differences in exercise performance, quality of life, exacerbation frequency, dyspnea 
and pulmonary imaging. BDR-FEV1 and BDR-FVC are associated with different clinical, 
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functional and radiological characteristics. Whether these BDR categories have prognostic 
implications remains to be tested. 
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Figure legends 
 
Figure 1. Mean FEV1 bronchodilator response in volume (L) and in percentage (%) by clusters 
of 100 individuals at each point as baseline FEV1 % predicted increases for the 6,107 participants 
with positive BDR. Changes in volume (y1 axis: ¨FEV1L) and % (y2 axis: ¨FEV1%) differ 
markedly.  While ¨FEV1L increases rapidly to ~0.16L and stabilizes DWWKDWOHYHO¨FEV1% 
fraction gradually declines in a hyperbolic fashion from 16% to 4%. BDR, bronchodilator 
response. FEV1, forced expiratory volume in 1 second; ', delta; %, percentage; L, liters.  
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Figure 2. Distribution of change in absolute volume for largest of three pre- to post 
bronchodilator FEV1 differences ('FEV1L) and change in FEV1% after bronchodilator in the 
whole study population (N=7,741). Dashed vertical lines represent the limits of the new BDR 
grading system (negative (0.00% or /), minimal (>0.00% to 9.00% or >0.00L to 
0.09L), mild (> 9.00% to 16.00% or > 0.09L to 0.16L, moderate (>16.00% to 26.00% or 
>0.16L to 0.26L), and marked (>26.00% or >0.26L)). Percentage of participants in each BDR 
category are given in between vertical lines that represent the limits of the BDR grading system. 
Curves were constructed as Gaussian fits on the histogram points consisting of 24 bins with 
equal distance of 0.0905 L spanning from -0.63 L to 1.45 L for 'FEV1L and 6.46% wide bins 
from -31.8% to 116.8% for 'FEV1% change. N.B.: To demonstrate the similarities and 
differences in distributions, only the segments from -0.4L to 0.6L and -40% to 60% changes are 
shown. MIN, minimal BDR category; MOD, moderate BDR category. 
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Figure 3. Response trend of 'FEV1 and 'FVC after bronchodilator in the total study population 
(N=7,741). Panel A shows response trend of mean change in absolute volume of 'FEV1L and 
'FVCL by 500 individuals at each point. Panel B shows response trend of mean change in 
'FEV1% and 'FVC% by 500 individuals at each point. In both panels, individuals are ordered 
by size of response. ', delta; FEV1, forced expiratory volume in 1 second; FVC, forced vital 
capacity; L, liters; %, percentage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
37 
 
Figure 4. Restricted cubic spline models of BDR (as separate continuous variables 'FEV1 L, 
'FEV1 %, 'FVC L and 'FVC %), with 95% confidence intervals (in gray) for 6MWD, Total 
SGRQ score and quantitative CT measures in the total study population. Panel A shows the 
adjusted models of BDR - FEV1L and BDR - FEV1% for 6MWD, SGRQ, WA segmental% and 
Pi15.  Panel B shows the adjusted models of BDR - FVCL and BDR - FVC % for SGRQ, 
emphysema% and gas trapping%.  'FEV1L,'FEV1%, 'FVCL, 'FVC %  were coded using a 
restricted cubic spline function with three knots, located at the 5th, 50th, and 95th percentiles. 
Models were adjusted for age, sex, race, smoking history, BMI, baseline FEV1 or FVC, and CT 
scanner type (for CT measures). 
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Tables  
 
Table 1. Characteristics of the study population  
 
Variables 6WXG\3RSXODWLRQ 1  
$JH\HDUV r 
6H[0DOH  
5DFH&DXFDVLDQ$IULFDQ$PHULFDQ  
%0,NJP r 
6PRNLQJKLVWRU\SDFN\HDUV,4UDQJH ± 
Pre-Bronchodilator Spirometry  
)(9/ r 
)(9SUHGLFWHG r 
)9&/ r 
)9&SUHGLFWHG r 
)(9)9& r 
)(9)9&Q  
Post-Bronchodilator Spirometry  
)(9/ r 
)(9SUHGLFWHG r 
)9&/ r 
)9&SUHGLFWHG r 
)(9)9& r 
)(9)9&Q  
Within Subject Coefficient of Variation Among 3 Forced Exhalations 
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&9IRUWKUHH3UH%')(9 r 
&9IRUWKUHH3UH%')9& r 
&9IRUWKUHH3RVW%')(9 r 
&9IRUWKUHH3RVW%')9& r 
Change after Bronchodilator  
')(9/ r 
')9&/ r 
')(9 r 
')9& r 
Mean r SD or median (interquartile range 25 - 75) presented as appropriate. Reported pulmonary 
function values are based on largest measurements. Definition of abbreviations: BMI, body mass 
index; CV, coefficient of variation (%); FEV1, forced expiratory flow volume in 1 second; FVC, 
forced vital capacity; ', delta or change; L, liters; BD, bronchodilator. 
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Table 2. Comparison of demographic characteristics, spirometry, functional exercise capacity, and quantitative CT measures of 
airway abnormality among various grades of FEV1 bronchodilator responders (N=7,741).  
 NEGATIVE MINIMAL MILD MODERATE MARKED 
Category range for 
'FEV1L (L) 
' FEV1   0 < ' FEV1  0.09 < ' FEV1  0.16 < ' FEV1  0.26 > ' FEV1 
Category range for 
'FEV1% (%) 
'% FEV1   >0 < '% FEV1  9 < '% FEV1  16 < '% FEV1  26 > '% FEV1  
N (%) 1634 (21.1) 2159 (27.9) 1549 (20) 1399 (18.1) 1000 (12.9) 
Demographics      
Age, yrs  59.1 r 8.6 60.8 r 8.9 60.9 r 9.0 60.6 r 9.1 59.0 r 8.7 
BMI, kg/m2 28.8 r 6.2 28.5 r 6.3 28.5 r 6.1 28.7 r 6.1 28.7 r 6.0 
Smoking history, 
pack years 
39.1 (27.7 ± 54.2) 40.0 (28.0 ± 55.5) 40.0 (27.0 ± 55.5) 40.0 (28.5 -55.5) 40.5 (30.0 ± 58.0) 
Sex, Male, % 55.3 48.1 47.8 57.2 66.8 
Race, Caucasian, % 64.8 72.7 76.2 76.6 74.8 
ICS use, % 6.7 6.2 5.5 6.9 9.3 
Spirometry  
Pre-BD FEV1, L 2.37 r 0.95 2.07 r 0.92 2.05 r 0.88 2.13 r 0.91 2.08 r 0.95 
Post-BD FEV1, L 2.28 r 0.93 2.12 r 0.93 2.17 r 0.88 2.32 r 0.93 2.43 r 0.98 
Pre-BD FVC, L 3.46 r 1.03 3.17 r 0.99 3.17 r 0.96 3.29 r 1.04 3.36 r 1.14 
Post-BD FVC, L 3.33 r 1.01 3.18 r 0.97 3.29 r 0.93 3.50 r 1.00 3.78 r 1.12 
'FEV1, L -0.09 r 0.09 0.04 r 0.02 0.12 r 0.02 0.20 r 0.04 0.36 r 0.12 
'FVC, L -0.14 r 0.24 0.02 r 0.19 0.12 r 0.21 0.21 r 0.24 0.41 r 0.37 
'FEV1, % -3.93 r 3.99 2.64 r 1.96 6.95 r 3.18 11.17 r 5.13 21.12 r 11.65 
'FVC, % -3.81 r 7.04 1.09 r 6.63 4.61 r 7.78 7.95 r 9.68 14.84 r 13.86 
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Pre-BD FEV1/FVC, 
% 
66.87 r 15.29 63.59 r 16.14 63.13 r 15.21 63.02 r 14.73 59.87 r 14.21 
Post-BD FEV1/FVC, 
% 
67.09 r 15.98 64.83 r 16.89 64.80 r 15.99 65.65 r 15.19 63.21 r 14.63 
Pre-BD FEV1, QC 3.15 r 1.05 3.60 r 0.67 3.71 r 0.59 3.66 r 0.65 3.61 r 0.72 
Post-BD FEV1, QC 3.68 r 0.68 3.74 r 0.58 3.68 r 0.60 3.55 r 0.69 3.26 r 0.97 
Pre-BD FVC, QC 3.07 r 1.14 3.42 r 0.82 3.48 r 0.77 3.43 r 0.85 3.34 r 0.89 
Post-BD FVC, QC 3.46 r 0.82 3.57 r 0.68 3.51 r 0.73 3.41 r 0.86 3.21 r 1.02 
Functional exercise capacity, quality of life, and exacerbation frequency  
6MWD, meters 413 r 123 408 r 123 418 r 118 429 r 120 431 r 117 
SGRQ score 20.61 (5.96 ± 43.27) 22.55 (6.30 ± 44.79) 21.74 (7.12 ± 43.50) 20.53 (6.45 ± 40.82)  25.35 (8.36 ± 46.27) 
mMRC 1.34 r 1.48 1.38 r 1.44 1.31 r 1.42 1.23 r 1.41 1.38 r 1.43 
Exacerbations/year 0.39 r 1.00 0.42 r 0.93 0.43 r 0.99 0.38 r 0.93 0.38 r 0.89 
Quantitative CT 
WAsegmental, % 61.13 r 3.32 61.17 r 3.21 61.26 r 3.19 61.40 r 3.14 62.12 r 3.38 
Pi15, SRWA 5.14 r 0.19 5.13 r 0.19 5.14 r 0.20 5.15 r 0.20 5.21 r 0.21 
Emphysema% 1.75 (0.56 ± 6.17) 2.40 (0.74 ± 9.49) 2.70 (0.76 ± 7.93) 2.61 (0.79 ± 8.01) 2.81 (0.97 ± 7.12) 
Gas trapping % 13.54 (6.01 ± 29.90) 15.10 (6.99 ± 35.47) 16.06 (7.54 ± 34.46) 16.47 (7.77 ± 34.14 19.35 (9.99 ± 36.12) 
Data are presented as mean r SD or median (IQR 25 ± 75) or as percentages. Definition of abbreviations: FEV1, forced expiratory 
flow volume in 1 seconds; FVC, forced vital capacity; ICS, inhaled corticosteroid; ', delta; L, liters; %, percentage; BD, 
bronchodilator; CT, computed tomography; WA, wall area; Pi15 SRWA, square root wall area of a 15 mm diameter airway; QC: 
quality control grades for spirometry maneuver (ranging from 0 to 4);  6MWD, six-minute walking distance; SGRQ, St. George 
Respiratory Questionnaire total score; mMRC, modified Medical Research dyspnea score. 
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Table 3. Adjusted multivariable analysis for functional exercise capacity, quality of life, exacerbation frequency, dyspnea and 
quantitative airway CT measures with increasing FEV1 and FVC bronchodilator response category, with negative response as 
reference. 
 
 
 BRONCHODILATOR RESPONSE GRADES ± FEV1 response 
 
N (%) 
 Negative 
1634 (21.1) 
Minimal 
2159 (27.9) 
Mild 
1549 (20.0) 
Moderate 
1399 (18.1) 
Marked 
1000 (12.9) 
6MWD Mean difference  
(95% CI) 
1 (ref) 8.46** 
(2.01 ± 14.91) 
17.60* 
(10.61 ± 24.58) 
26.94* 
(19.81 ± 34.07) 
37.00* 
(29.14 ± 44.86) 
SGRQ % difference  
(95% CI) 
eE 
1 (ref) -7.30** 
(-13.00 ± -1.20) 
0.927 
-8.30** 
(-14.40 ± -1.80) 
0.917 
-12.20* 
(-18.20 ± -5.80) 
0.878 
-12.40* 
(-18.90 ± -5.30) 
0.876 
mMRC  OR (95% CI) 1 (ref) 0.81** 
(0.71 ± 0.93) 
0.74* 
(0.64 ± 0.86) 
0.62* 
(0.53 ± 0.73) 
0.63* 
(0.53 ± 0.75) 
Exacerbations/year RR (95% CI) 1 (ref) 0.89 
(0.78 ± 1.01) 
0.91 
(0.79 ± 1.05) 
0.86** 
(0.74 ± 0.99) 
0.74* 
(0.63 ± 0.87) 
WAsegmental, % Mean difference  
(95% CI) 
1 (ref) -0.24** 
(-0.43 ± -0.06) 
-0.18 
(-0.38 ± 0.01) 
-0.08 
(-0.28 ± 0.12) 
0.29** 
(0.06 ± 0.51) 
Pi15 Mean difference  
(95% CI) 
1 (ref) -0.01** 
(-0.03 ± -0.00) 
-0.00 
(-0.02 ± 0.01) 
-0.00 
(-0.01 ± 0.01) 
0.03* 
(0.01 ± 0.04) 
Emphysema% % difference  
(95% CI) 
eE 
1 (ref) 7.62 (-1.62 ± 12.71) 
1.08  
5.30 
(-4.41 ± 15.99) 
1.05  
3.75 
(-6.06 ± 14.60) 
1.04  
-6.00 
(-15.83 ± 4.97) 
0.95  
Gas trapping% % difference  
(95% CI) 
eE 
1 (ref) -2.69 (-8.57 ± 3.57) 
0.97 
1.54 (-5.06 ± 8.60) 
1.01 
4.00 (-2.92 ± 
11.41) 
1.04 
10.50 (2.37 ± 
19.28) 
1.10** 
 
 BRONCHODILATOR RESPONSE GRADES ± FVC response 
 
N (%) 
 Negative 
2885 (37.3) 
Minimal 
1273 (16.4) 
Mild 
928 (12.0) 
Moderate 
935 (12.1) 
Marked 
1720 (22.2) 
6MWD Mean difference  
(95% CI) 
1 (ref) 4.65 
(-2.17  ± 11.48) 
2.38 
(-5.27 ± 10.03) 
4.42 
(-3.26 ± 12.10) 
13.91* 
(7.56 ± 20.27) 
SGRQ % difference  
(95% CI) 
eE 
1 (ref) 4.97  
(-2.28 -12.63) 
1.05 
4.37  
(-3.50 ± 12.89) 
1.04 
9.39 
 (1.16 ± 18.29) 
1.09** 
14.33  
(7.19 ± 21.95) 
1.14* 
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mMRC  OR  
(95% CI) 
1 (ref) -0.03 
(-0.09 ± 0.03) 
0.07 
(-0.01 ± 0.15) 
0.12** 
(0.03 ± 0.21) 
0.20* 
(0.09 ± 0.30) 
Exacerbations/year RR  
(95% CI) 
1 (ref) 0.06 
(-0.07 ± 0.19) 
0.16** 
(0.01 ± 0.30) 
0.20** 
(0.05 ± 0.34) 
0.17** 
(0.05 ± 0.29) 
WAsegmental, % Mean difference  
(95% CI) 
1 (ref) -0.10 
(-0.29 ± 0.09) 
0.11 
(-0.10 ± 0.33) 
0.27 
(0.05 ± 0.49) 
0.67* 
(0.49 ± 0.85) 
Pi15 Mean difference  
(95% CI) 
1 (ref) -0.02** 
(-0.03 ± -0.01) 
-0.01 
(-0.02 -0.01) 
0.12 
(-0.00 ± 0.03) 
0.04* 
(0.03 ± 0.05) 
Emphysema% % difference  
(95% CI) 
eE 
1 (ref) 23.82  
(12.03 ± 36.84) 
1.24* 
27.44  
(13.99 ± 42.47) 
1.27* 
40.50  
(25.70 ± 57.04) 
1.40* 
50.29  
(37.00 ± 64.88) 
1.50* 
Gas trapping% % difference  
(95% CI) 
eE 
1 (ref) 10.33  
(2.90 ± 18.31) 
1.10** 
19.83  
(10.75 ± 29.65) 
1.20* 
26.51  
(17.07 ± 36.71) 
1.26* 
46.21  
(37.09 ± 55.94)* 
1.46 
 
Mean value of the outcome is modeled; regression coefficient corresponds to mean difference of the outcome. The mean value of the 
outcome variables (6MWD, WA% and Pi15) increases/decreases by the amount of the regression coefficient in the particular BDR 
category compared to the reference category (negative response to bronchodilator). SGRQ, emphysema% and gas trapping% were 
natural log transformed. The displayed coefficients (% difference and CI 95%) for SGRQ, emphysema% and gas trapping% were 
back-transformed regression coefficients (eE) that correspond to the relative ratio between the two groups in percent. For example for 
SGRQ, the mean SGRQ total score of marked bronchodilator responders are 12.4% lower than that of the reference category. OR 
indicates the relative odds increase for a higher score of mMRC between the two groups. For example, the estimated odds of having a 
one unit higher score of mMRC dyspnea score for marked bronchodilator responders is 0.63 of the odds compared with participants 
with a negative bronchodilator response. RR indicates the relative risk decrease in number of exacerbations/year between the risk 
group and the reference category. For example, relative risk of number of exacerbations/year is 26% decreased in marked 
bronchodilator responders compared to that of the reference category. Participants with a negative bronchodilator response are stated 
as reference category.  
All models were controlled for sex, age, race, body mass index, smoking history, and initial pre-bronchodilator FEV1. Additionally, 
models with CT outcomes were adjusted for CT scanner type. Significant associations are marked as bold. * P < 0.0001; ** P < 0.05. 
Definition of abbreviations: 6MWD, six-minute walking distance; m, meters CI, confidence interval; SGRQ, St. George Respiratory 
Questionnaire total score; mMRC, modified Medical Research dyspnea score; WA, wall area; Pi15, square root wall area of a 15 mm 
diameter airway; OR, Odds ratio; RR, relative risk. 
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Table 4. Comparison of bronchodilator responses using ATS/ERS guidelines (¨FEV1L t0.2L and ¨FEV1% t12%, or ¨FVC t 0.2L 
and ¨FVC% t12%)
 
and proposed bronchodilator response grades (based on range of ¨FEV1L or ¨FEV1%).  
 BDR GRADES 
 Negative Minimal Mild Moderate Marked 
Total number of participants 1634 2159 1549 1399 1000 
Only ¨FEV1% t 12% 0 0 146 489 769 
Only ¨FVC% t 12% 27 121 216 345 505 
Only ¨FEV1L t 0.2 L 0 0 0 632 955 
Only ¨FVCL t 0.2 L 88 269 448 663 761 
¨FEV1L t 0.2L and ¨FEV1% t 12% 0 0 0 224 724 
¨FVCL t 0.2L
 
and
 
¨FVC% t 12% 26 111 215 338 501 
BDR (+) by ATS/ERS                                   
¨FEV1L t 0.2L and ¨FEV1% t 12% or 
¨FVCL t 0.2L
 
and ¨FVC% t 12% 
26 111 215 452 794 
Numbers of participants in each particular category is presented. Definition of abbreviations: BDR, bronchodilator response; FEV1, 
forced expiratory flow volume in 1 seconds; %, percentage; FVC, forced vital capacity; L, liters; ATS/ERS, American Thoracic 
Society/European Respiratory Society.  
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All models were controlled for sex, age, race, body mass index, smoking history, and initial pre-bronchodilator FEV1. Additionally, 
models with CT outcomes were adjusted for CT scanner type. Significant associations are marked as bold. * P < 0.0001;  P < 0.05. 
Definition of abbreviations: 6MWD, six-minute walking distance; m, meters CI, confidence interval; SGRQ, St. George Respiratory 
Questionnaire total score; mMRC, modified Medical Research dyspnea score; WA, wall area; Pi15, square root wall area of a 15 mm 
diameter airway; OR, Odds ratio; RR, relative risk. 
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Methods 
Inclusion and exclusion criteria 
10,311 male and female non-Hispanic White and African-American participants, 45 to 
80 years old, with at least 10 pack-years of smoking history were included in the study. 
Exclusion criteria were history of other lung disease (except asthma), previous lung resection 
or lung volume reduction surgery, active cancer treatment, suspected lung cancer, metal in the 
chest that would interfere with CT scanning, presence of chest radiotherapy history and 
pregnancy1. 
 
Spirometry and quality control  
Spirometry tests were performed by using an ultrasound-based spirometer (NDD, EasyOne 
Spirometer Medizintechnik AG, Zurich, Switzerland) before and after administration of short-
acting E2-agonist (albuterol) in accordance with the ERS/ATS recommendations2. Spirometric 
measurements were reviewed and graded (ranging from 0  4) by an automated quality 
assessment software package and by a centralized quality control process established for the 
COPDGene project3.   
 
Correlative measures 
CT scans were acquired at full inspiration and after tidal expiration according to a 
standardized protocol1. Airway abnormality was assessed by segmental airway wall area 
percentage: segmental WA% = (outer bronchus area ޤDLUZD\OXPLQDODUHD(outer bronchus 
area) by XVLQJµ3XOPRQDU\:RUNVWDWLRQ3OXV¶VRIWZDUH9,'$'LDJQRVWLFV&RUDOYLOOH,$
U.S.A.)8. Airway wall thickness was assessed by square root of wall area of a 15mm diameter 
airway (Pi15) by 3D SLICER9. Per the COPDGene protocol, CT scans were done last on the 
3 
 
visit day, after all pulmonary function and other functional tests and symptom assessment 
questionnaires. 
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Table E1. Comparison of demographic characteristics, spirometry, functional exercise capacity, and quantitative CT measures of airway 
abnormality among various grades of FVC bronchodilator responders (N=7,741). 
 BRONCHODILATOR RESPONSE GRADES ± FVC response 
 NEGATIVE MINIMAL MILD MODERATE MARKED 
Category range for 
'FVC (L) 
' )9& 0 < ' )9& 0.09 < ' )9& 0.16 < ' )9& 0.26 > ' FVC 
Category range for 
'FVC% (%) 
'% FVC
 1   >0 < ')9& 9 < ')9& 16 < ')9& 26 > '% FVC 
N (%) 2885 (37.3) 1273 (16.4) 928 (12.0) 
935 (12.1) 
1720 (22.2) 
Demographics      
Age, yrs  58.8 r 8.8 60.3 r 8.8 60.7 r 9.0 60.9 r 8.7 61.4 r 9.1 
BMI, kg/m2 28.6 r 6.0 
 
28.8 r 6.3 28.7 r 6.3 29.1 r 6.4 28.3 r 5.9 
Smoking history, 
pack years 
37.3 (25.1 ± 52.0) 
38.9 (27.1 ± 54.0) 40.5 (29.3 ± 55.9) 40.7 (30.0 -57.4) 43.4 (31.7 ± 60.0) 
Sex, Male, % 54.8 47.3 49.5 
55.7 61.2 
Race, Caucasian, % 66.3 76.2 73.7 75.7 
79.0 
ICS use, % 4.7 6.7 
6.7 7.2 9.9 
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Spirometry  
Pre-BD FEV1, L 2.42 r 0.90 2.13 r 0.89 2.03 r 0.90 1.97 r 0.90 1.82 r 0.88 
Post-BD FEV1, L 2.44 r 0.91 2.22 r 0.92 2.14 r 0.93 2.11 r 0.93 2.05 r 0.92 
Pre-BD FVC, L 3.53 r 1.02 3.22 r 1.00 3.12 r 0.98 3.10 r 1.00 3.06 r 1.00 
Post-BD FVC, L 3.37 r 1.00 3.27 r 1.00 3.25 r 0.99 3.31 r 1.00 3.54 r 1.04 
'FEV1, L -0.01 r 0.12 0.08 r 0.10 0.11 r 0.10 0.14 r 0.11 0.23 r 0.15 
'FVC, L -0.17 r 0.18 0.04 r 0.02 0.12 r 0.02 0.21 r 0.03 0.48 r 0.26 
'FEV1, % 0.53 r 5.82 4.27 r 5.18 6.44 r 5.90 8.27 r 7.03 15.19 r 11.43 
'FVC, % -4.85 r 4.91 1.55 r 1.08 4.42 r 1.81 7.46 r 3.00 17.55 r 10.97 
Pre-BD FEV1/FVC, 
% 
67.44 r 13.90 64.60 r 15.19 63.03 r 15.31 61.77 r 15.90 57.75 r 15.80 
Post-BD FEV1/FVC, 
% 
71.05 r 13.97 66.22 r 15.47 64.13 r 15.42 62.12 r 15.90 56.57 r 15.49 
Functional exercise capacity, quality of life, and exacerbation frequency  
6MWD, meters 428 r 122 419 r 122 407 r 124 404 r 119 410 r 115 
SGRQ score 16.34 (4.21 ± 38.60) 19.91 (6.26 ± 41.59) 24.20 (7.26 ± 44.46) 25.94 (9.19 ± 47.10)  29.59 (11.78 ± 49.87) 
mMRC 1.14 r 1.39 1.25 r 1.40 1.41 r 1.45 1.50 r 1.47 1.60 r 1.47 
Exacerbations/year 0.30 r 0.81 0.40 r 0.95 0.45 r 1.03 0.50 r 1.06 0.51 r 1.04 
Quantitative CT 
WAsegmental, % 60.79 r 3.21 61.03 r 3.14 61.44 r 3.18 61.75 r 3.29 62.21 r 3.22 
Pi15, SRWA 5.12 r 0.19 5.11 r 0.19 5.14 r 0.19 5.17 r 0.20 5.20 r 0.21 
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Emphysema% 1.54 (0.54 ± 4.83) 2.37 (0.79 ± 6.77) 
2.74 (0.77 ± 9.48) 3.18 (0.91 ± 10.52) 4.10 (1.89 ± 13.04) 
Gas trapping % 11.83 (5.45 ± 24.19) 14.28 (6.56 ± 30.11) 
16.57 (7.61 ± 34.28) 18.58 (8.63 ± 39.82) 26.21 (12.34 ± 45.81) 
 
Data are presented as mean r SD or median (IQR 25 ± 75) or as percentages. Definition of abbreviations: FEV1, forced expiratory flow volume 
in 1 seconds; FVC, forced vital capacity; ICS, inhaled corticosteroid; ', delta; L, liters; %, percentage; BD, bronchodilator; CT, computed 
tomography; WA, wall area; Pi15 SRWA, square root wall area of a 15 mm diameter airway; QC: quality control grades for spirometry maneuver 
(ranging from 0 to 4);  6MWD, six-minute walking distance; SGRQ, St. George Respiratory Questionnaire total score; mMRC, modified 
Medical Research dyspnea score. 
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Baylor College of Medicine Institutional Review Board for Baylor 
College of Medicine and Affiliated Hospitals 
H-22209 
Michael E. DeBakey VAMC Institutional Review Board for Baylor College of Medicine and 
Affiliated Hospitals 
H-22202 
Columbia University Medical 
Center 
Columbia University Medical Center IRB IRB-AAAC9324 
Duke University Medical Center The Duke University Health System Institutional Review 
Board for Clinical Investigations (DUHS IRB) 
Pro00004464 
Johns Hopkins University Johns Hopkins Medicine Institutional Review Boards (JHM 
IRB) 
NA_00011524 
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Los Angeles Biomedical Research 
Institute 
The John F. Wolf, MD Human Subjects Committee of Harbor-
UCLA Medical Center 
12756-01 
Morehouse School of Medicine Morehouse School of Medicine Institutional Review Board 07-1029 
Temple University Temple University Office for Human Subjects Protections 
Institutional Review Board 
11369 
University of Alabama at 
Birmingham 
The University of Alabama at Birmingham Institutional 
Review Board for Human Use 
FO70712014 
University of California, San Diego University of California, San Diego Human Research 
Protections Program 
070876 
University of Iowa The University of Iowa Human Subjects Office 200710717 
Ann Arbor VA VA Ann Arbor Healthcare System IRB PCC 2008-110732 
University of Minnesota 8QLYHUVLW\RI0LQQHVRWD5HVHDUFK6XEMHFWV¶3URWHFWLRQ
Programs (RSPP) 
0801M24949 
University of Pittsburgh University of Pittsburgh Institutional Review Board PRO07120059 
University of Texas Health Sciences 
Center at San Antonio 
UT Health Science Center San Antonio Institutional Review 
Board 
HSC20070644H 
Health Partners Research 
Foundation 
Health Partners Research Foundation Institutional Review 
Board 
07-127 
University of Michigan Medical School Institutional Review Board (IRBMED) HUM00014973 
Minneapolis VA Medical Center Minneapolis VAMC IRB  4128-A 
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Fallon Clinic Institutional Review Board/Research Review Committee    
Saint Vincent Hospital ± Fallon Clinic ± Fallon Community 
Health Plan 
1143 
 
